Sam Chun Dang Pharm's Oral Keytruda Plan Met With Skepticism, MSD Denies Talks
Translated from Korean, summarized and contextualized by DistantNews.
At a glance
News
Sources not specified
Context piece
- Sam Chun Dang Pharm presented a plan to develop an oral form of Keytruda, a top-selling cancer drug, to overseas investors.
- Merck & Co. (MSD), the drug's owner, denied any discussions about developing an oral version, calling the company's claims unfounded.
- Questions remain about the feasibility and core data supporting Sam Chun Dang Pharm's development proposal.
South Korean pharmaceutical company Sam Chun Dang Pharm has reportedly presented a blueprint to overseas investors for developing an oral pill version of Keytruda, the world's top-selling cancer drug. This announcement has garnered significant market attention.
However, the feasibility of this ambitious project is being questioned. Merck & Co. (MSD), the pharmaceutical giant that owns Keytruda, has officially denied any ongoing discussions regarding the development of an oral formulation. MSD stated that the company's claims are "groundless."
There are no discussions regarding the development of an oral formulation.
Further scrutiny revealed that the core data presented by Sam Chun Dang Pharm to support its development proposal appears to be merely a placeholder. This raises doubts about the substance and validity of the company's claims, suggesting a need for rigorous verification before the market fully embraces the concept.
It is groundless.
DistantNews Editorial
Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.
More Stories
From Our Blog
What Gets Lost (and Found) When News Is Translated
The Critical Role of Diaspora Media in Global News
What Travellers Should Know About Countries with Restricted Press
A Digital Nomad's Guide to Following Local News
How the Same Story Looks Different in Different Countries
